Secukinumab receives FDA approval for psoriatic arthritis, ankylosing spondylitis
The Food and Drug Administration approved two new indications for the interleukin-17A inhibitor secukinumab (Cosentyx) – psoriatic arthritis in adults and ankylosing spondylitis in adults – on Jan. 15. These join the approval for moderate to severe plaque psoriasis in adults it received in January...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Ankylosing Spondylitis | Arthritis | Dermatology | Food and Drug Administration (FDA) | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin